BenzingaOctober 22, 2026 at 12:07 PM NY5 Days Ago
Gilead Sciences Agrees To Acquire Oral IL-23R Inhibitor Program From PepStar Therapeutics Under $1.275B Deal
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
